Addyi Cost in Mississippi 2026: Prices, Insurance, Medicaid, and Compounded Flibanserin

What Is Flibanserin and Who Is It For?

Flibanserin is the only FDA-approved non-hormonal medication for hypoactive sexual desire disorder (HSDD) in premenopausal women. The drug works centrally, acting as a serotonin 1A agonist and serotonin 2A antagonist to modulate dopamine and norepinephrine in the prefrontal cortex, a mechanism distinct from any hormonal or phosphodiesterase pathway. [1]

The FDA granted approval on August 18, 2015, under the brand name Addyi (Sprout Pharmaceuticals), specifically for acquired, generalized HSDD in premenopausal women who have not used a serotonergic drug or moderate-to-strong CYP3A4 inhibitor within two weeks. [2] HSDD is defined in the DSM-5 (now merged into Female Sexual Interest/Arousal Disorder, FSIAD) as persistently low or absent sexual desire that causes marked personal distress. [3]

The BEGONIA trial (J Sex Med, 2014; N=1,378) showed flibanserin 100 mg nightly produced a statistically significant increase in satisfying sexual events (SSEs) compared with placebo over 24 weeks, with a treatment difference of approximately 0.5 SSEs per 28 days (P<0.001). [4] A patient-reported distress score (Female Sexual Distress Scale-Desire/Arousal/Orgasm) also improved significantly in the active arm. [4] The drug does not work acutely. Patients typically need 8 to 12 weeks of nightly dosing before evaluating response. [2]

Prescribers in the U.S. must complete a Risk Evaluation and Mitigation Strategy (REMS) certification due to the severe hypotension and syncope risk when flibanserin is combined with alcohol or CYP3A4 inhibitors such as fluconazole. [2] Certified prescribers dispense exclusively through REMS-enrolled pharmacies. [2]

How Much Does Addyi Cost in Mississippi in 2026?

Brand-name Addyi carries a manufacturer list price of approximately $880 per month in Mississippi, which translates to roughly $10,560 per year without insurance or manufacturer assistance. Cash-pay prices at major Mississippi retail pharmacies mirror that list price closely; there is no meaningful retail discount available to uninsured patients who present without a coupon or savings program.

For context, national data from the FDA's Orange Book and commercial pharmacy benefit managers place Addyi in a specialty or non-preferred brand tier, where plan-level cost sharing commonly ranges from $150 to $400 per month for commercially insured patients who have coverage at all. [2] Mississippi has no state mandate requiring private insurers to cover HSDD pharmacotherapy, so coverage decisions are left entirely to individual plan formularies.

Patients who pay cash at Mississippi pharmacies should always check GoodRx, RxSaver, or the manufacturer's own savings portal before filling, as third-party discount cards can reduce the out-of-pocket cost by 10 to 20 percent in some cases, though the drug rarely drops below $700 without manufacturer assistance. [5]

The FDA Office of Women's Health notes that cost and access barriers disproportionately affect rural populations, a relevant concern for Mississippi, where 51.2 percent of residents live in rural or micropolitan areas according to 2020 U.S. Census data. [6]

Does Mississippi Medicaid Cover Addyi?

Mississippi Medicaid does not cover flibanserin (Addyi) as of 2026. The Mississippi Division of Medicaid's preferred drug list does not include flibanserin in any therapeutic category, and no published prior-authorization pathway exists for the drug within the state Medicaid program. [7]

This exclusion is not unique to Mississippi. Medicaid coverage for Addyi is limited nationally. The drug falls outside most state Medicaid formularies because HSDD has historically been classified as a quality-of-life rather than a medically necessary condition by pharmacy benefit reviewers, a classification the North American Menopause Society (NAMS) and the International Society for the Study of Women's Sexual Health (ISSWSH) have contested in published position statements. [8]

The ISSWSH published a clinical practice guideline in 2021 stating, "HSDD is a medical condition with significant negative impact on quality of life, relationships, and psychological well-being, and its pharmacologic treatment should be considered medically necessary." [8] Mississippi Medicaid has not adopted this framing in its formulary decisions through early 2026.

Dual-eligible patients (those on both Medicare and Medicaid) face the same coverage gap. Medicare Part D also does not cover drugs indicated exclusively for sexual dysfunction per statute (42 U.S.C. §1395w-102(e)(2)(A)), making flibanserin ineligible for Part D reimbursement regardless of state. [9]

Patients on Mississippi Medicaid who cannot afford brand Addyi should discuss compounded flibanserin with a licensed prescriber, as explored in the section below.

Is Compounded Flibanserin Legal in Mississippi?

Yes. Compounded flibanserin is legally available in Mississippi through state-licensed 503A compounding pharmacies, provided specific conditions are met. This is one of the most cost-effective options for Mississippi patients without commercial insurance coverage.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed pharmacist may compound flibanserin upon receipt of a valid patient-specific prescription from a certified REMS prescriber, as long as the pharmacy does not compound the drug in anticipation of prescriptions (i.e., no bulk compounding for office stock) and uses pharmaceutical-grade active pharmaceutical ingredient (API). [10] The pharmacy must hold a Mississippi State Board of Pharmacy permit and comply with USP <795> standards for non-sterile compounding. [11]

Flibanserin is not on the FDA's list of drugs that may not be compounded under 503A (the "difficult to compound" or "essentially a copy" lists as of 2026), so 503A compounding is permissible. [10] Cost at 503A pharmacies varies widely. Some telehealth platforms that partner with 503A compounders offer compounded flibanserin for $0 to $99 per month, depending on membership fees and the platform's pharmacy partnerships.

Patients should confirm that any 503A pharmacy they use is licensed with the Mississippi State Board of Pharmacy. [11] Out-of-state 503A pharmacies shipping into Mississippi must hold a non-resident pharmacy permit from the same board. [11] The prescription itself must originate from a REMS-certified prescriber, whether that prescriber is in Mississippi or another state, as long as the prescriber holds a valid DEA registration covering the patient's state of residence. [2]

Which Insurance Plans Cover Addyi in Mississippi?

Commercial insurance coverage for Addyi in Mississippi varies plan by plan, and no blanket rule applies. Large employer-sponsored plans governed by ERISA set their own formularies without state mandate oversight, meaning that two employees at different Mississippi companies may have opposite coverage outcomes for the exact same drug.

Blue Cross Blue Shield of Mississippi, the state's dominant commercial insurer, does not list flibanserin on its 2026 standard formulary tiers reviewed by the HealthRX medical team. Humana and Aetna plans operating in Mississippi typically place Addyi on a non-formulary tier requiring prior authorization and step-therapy documentation that a patient has tried and failed at least one other HSDD-related intervention (often sexual counseling or a serotonergic washout protocol). [12]

The following framework applies to Mississippi patients attempting to obtain insurance coverage for Addyi:

1. Confirm your plan's formulary tier for flibanserin by calling the member services number on your insurance card or checking the online formulary tool.
2. Ask your REMS-certified prescriber to submit a prior-authorization request citing the BEGONIA trial data [4] and the ISSWSH 2021 clinical practice guideline. [8]
3. If denied, request a peer-to-peer review between your prescriber and the plan's medical director.
4. If the peer-to-peer review fails, file a formal appeal citing medical necessity under the plan's appeals process.
5. If the appeal is denied, apply for the Sprout Pharmaceuticals savings card (see below) or shift to compounded flibanserin via a 503A pharmacy.

The Affordable Care Act (ACA) requires non-grandfathered individual and small-group plans to cover preventive services rated A or B by the U.S. Preventive Services Task Force (USPSTF) at no cost, but HSDD pharmacotherapy does not currently carry a USPSTF grade. [13] That means no ACA mandate forces Mississippi plans to cover Addyi.

How Does the Sprout Pharmaceuticals Savings Card Work in Mississippi?

The Sprout Pharmaceuticals commercial savings card (also marketed as the "Addyi Savings Program") is available to commercially insured Mississippi patients who meet eligibility criteria. The program may reduce a patient's monthly co-pay to as low as $0 for the first fill or to a fixed monthly cap for subsequent fills, though terms change periodically and should be verified at Sprout's official patient assistance page.

Key eligibility restrictions apply. The savings card is not valid for patients covered by any federal or state government health program, including Mississippi Medicaid, Medicare Part D, CHIP, or TriCare. [14] Patients must be U.S. residents, have a valid prescription from a REMS-certified prescriber, and fill the prescription at a REMS-enrolled pharmacy.

The card works as a secondary payer at the pharmacy point of sale. The pharmacy runs the patient's primary insurance first. If the plan pays nothing (non-formulary denial) or leaves a co-pay, the savings card is applied to the remaining balance up to the program's monthly maximum. Patients who pay entirely out of pocket (no insurance) may qualify for Sprout's separate patient assistance program, which requires income documentation and has historically covered full drug costs for patients at or below 400 percent of the federal poverty level, though Mississippi patients should confirm current income thresholds directly with Sprout. [14]

For Mississippi residents, the savings card can be obtained at the prescriber's office, downloaded from Sprout's website, or provided by a telehealth platform that partners with REMS-enrolled pharmacies.

Can I Get Addyi via Telehealth in Mississippi?

Yes. Telehealth prescribing of flibanserin is fully legal in Mississippi. The Mississippi State Board of Medical Licensure permits prescribing via synchronous audio-video telehealth for non-controlled substances, and flibanserin is not a scheduled controlled substance. [15] A prescriber licensed in Mississippi (or holding a multi-state compact license covering Mississippi) may conduct a telehealth visit, obtain informed consent for the REMS program, certify as a REMS prescriber, and transmit an electronic prescription to a REMS-enrolled pharmacy.

The REMS program requires the prescriber to counsel the patient about the alcohol contraindication, the 8-hour waiting period between the last drink and the dose, and the risk of syncope and hypotension if CNS depressants or CYP3A4 inhibitors are co-administered. [2] This counseling can occur entirely via telehealth video call and does not require an in-person office visit.

Several national telehealth platforms (including those partnering with 503A compounders) offer flibanserin prescriptions and subsequent fills through Mississippi-licensed prescribers. Typical visit fees range from $25 to $100 for the initial consultation, with subscription models bundling the consultation and the compounded medication for a flat monthly fee.

Mississippi does not impose a telemedicine-specific prescription restriction beyond the standard prescribing requirements that apply in all settings. [15] Patients must present to the telehealth visit with a valid government-issued ID confirming Mississippi residency, and the prescriber must document that an appropriate patient-provider relationship has been established via the telehealth encounter before transmitting the first prescription.

What Is the Cheapest Way to Get Addyi in Mississippi?

The cheapest evidence-based path to flibanserin in Mississippi in 2026 is compounded flibanserin from a licensed 503A pharmacy, obtained via a telehealth visit. Patients who pursue this route may pay $0 to $99 per month depending on platform membership fees, compared with $880 per month for brand Addyi at retail. [10]

For patients who specifically want brand-name Addyi and carry commercial insurance, the lowest realistic out-of-pocket cost comes from combining insurance coverage (even partial) with the Sprout savings card. Patients with commercial plans that carry a $50 monthly co-pay, for example, may reduce that figure to near $0 per month with a current savings card. [14]

Patients on Mississippi Medicaid face the fewest options. Medicaid exclusion blocks the savings card. Out-of-pocket brand Addyi at $880 is not feasible for most Medicaid-eligible patients. Compounded flibanserin via a 503A pharmacy is the only cost-accessible route, provided the patient can access a REMS-certified prescriber, which telehealth platforms make possible statewide. [10] [15]

A published 2022 analysis in the Journal of Sexual Medicine examining access disparities in HSDD treatment found that rural, low-income, and Southern U.S. patients were 2.3 times less likely to receive a flibanserin prescription than urban, higher-income patients, even after controlling for diagnosis rate. [16] Mississippi patients face structural access barriers beyond cost alone, including physician unfamiliarity with REMS certification and limited ob-gyn specialist density in rural counties.

Alcohol Interaction and Safety: What Mississippi Patients Must Know

The FDA placed a black-box warning on flibanserin's label specifically for the interaction with alcohol, which can cause severe hypotension, syncope, and accidental injury. [2] This is not a mild interaction. In clinical pharmacology studies, 25 percent of subjects who consumed alcohol with flibanserin experienced hypotension or syncope compared with 2 percent on placebo. [17]

The prescribing label instructs patients to avoid alcohol entirely while taking flibanserin. [2] Because of this risk, the FDA's REMS program for Addyi requires prescribers to educate patients that they must not drink alcohol on any day they take flibanserin, and that if they plan to drink, they should skip that evening's dose and resume the following night.

Other drugs that interact significantly include fluconazole (a 7-fold increase in flibanserin exposure), oral contraceptives containing ethinyl estradiol, and moderate CYP3A4 inhibitors such as erythromycin, grapefruit juice, and ciprofloxacin. [2] Mississippi prescribers and telehealth platforms must review the patient's medication list before issuing a REMS certification.

The most common non-interaction adverse effects reported in phase 3 trials were dizziness (11.4 percent), somnolence (11.2 percent), nausea (10.4 percent), and fatigue (9.2 percent), all significantly higher than placebo rates. [4] These rates dropped over time, generally stabilizing after the first four to six weeks of nightly dosing.

Clinical Efficacy: What the Trials Show

Three key phase 3 trials formed the basis of FDA approval: BEGONIA (N=1,378), VIOLET (N=1,267), and DAISY (N=1,144). [4] [18] [19] Across all three trials, flibanserin 100 mg nightly produced statistically significant improvements versus placebo in SSEs, sexual desire scores, and distress scores after 24 weeks of treatment.

The BEGONIA trial (J Sex Med, 2014) showed a treatment difference of approximately 0.5 SSEs per 28 days (P<0.001) and a statistically significant improvement on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) total score. [4] The FDA's own advisory committee review noted that while the absolute effect size is modest, the population with HSDD has no other approved non-hormonal pharmacologic option, making even a moderate effect clinically meaningful for appropriately selected patients. [2]

Real-world observational data from a 2021 claims-based study (N=4,200 women who filled at least one flibanserin prescription) found that 58 percent of patients continued treatment at six months, a retention rate comparable to other chronic condition medications with similar efficacy profiles. [20]

Mississippi-Specific Access Summary

Mississippi residents face a specific combination of barriers: no Medicaid coverage, limited specialty prescriber density in rural areas, and a brand list price that matches the national high. The practical options in order of increasing cost are: compounded flibanserin via telehealth and a 503A pharmacy ($0 to $99/month), brand Addyi with commercial insurance plus the Sprout savings card (variable, potentially $0 to $50/month), and brand Addyi cash-pay ($880/month).

Telehealth access removes the geographic barrier for most patients. A Mississippi resident in Clarksdale or Hattiesburg has the same telehealth access to a REMS-certified prescriber as a resident in Jackson. [15] The prescriber-side REMS certification process takes approximately 30 minutes online via the Addyi REMS portal and does not require special DEA scheduling authority because flibanserin is not a controlled substance. [2]

Patients should ask any prospective telehealth platform whether their partner pharmacy is enrolled in the Addyi REMS program before completing a visit, since a non-enrolled pharmacy cannot legally dispense the brand product. [2] Compounded flibanserin from a 503A pharmacy is not subject to REMS dispensing requirements at the pharmacy level, though the prescriber must still be REMS-certified for the brand drug before prescribing flibanserin in any form. [2] [10]